Dr. Umar

This large metagenomic study identified widespread gut microbiome dysbiosis in Parkinson’s disease, with specific microbial and functional signatures linked to inflammation, neurodegeneration, and disease progression, offering concrete targets for future clinical interventions and biomarker discovery.

This case-control study identified distinct gut microbiome signatures in Parkinson’s disease, including reduced diversity and increased abundance of key phyla (Proteobacteria, Verrucomicrobiota/Akkermansia) and metabolic pathways, with microbial profiles varying by disease subtype and duration—suggesting clinical relevance for microbiome-based biomarkers in PD.

Study of altered gut microbiota in Parkinson’s disease with motor complications shows decreased Blautia and increased Lactobacillus in patients with wearing-off, suggesting specific microbial signatures linked to advanced PD.

This study demonstrated that combining gut microbiome profiles and dietary carbohydrate intake significantly improves the prediction of Parkinson’s disease, identifying key microbial taxa alterations and their clinical associations, supporting integrated biomarker strategies for diagnosis and management.

This year-long study shows persistent loss of butyrate-producing gut bacteria in Parkinson’s disease, with microbiome differences stable over time and modestly enhanced prediction of progression when combined with dietary data. Device-assisted therapies had variable, non-sustained microbiome impacts.

This study characterizes gut microbiota and metabolome differences across Parkinson’s disease motor phenotypes, identifying specific microbial and metabolic signatures associated with tremor dominant versus non-tremor dominant forms, and highlighting their potential role in disease progression and symptom severity.

This study shows that Parkinson’s disease is associated with decreased gut SCFA production, increased intestinal inflammation, and altered microbiome composition, with significant links to disease onset and severity. Findings suggest microbiome-mediated mechanisms may be key to PD progression and represent targets for intervention.

This study identifies distinct gut microbiome and metabolic signatures in Parkinson’s disease, highlighting decreased microbial folate biosynthesis and increased homocysteine production as key features, with implications for disease progression and potential clinical interventions.

This prospective study demonstrates that fecal microbiota transplantation can correct gut dysbiosis and significantly improve both gastrointestinal and motor symptoms in Parkinson’s disease patients with constipation, supporting FMT’s role as a potential adjunctive therapy targeting the gut-brain axis.

Turkish case–control data show reduced Firmicutes/SCFA producers and increased Lactobacillus and Akkermansia in PD, with dysbiosis severity tracking disease duration and non-motor symptoms, supporting a mechanistic gut–brain link.

A multi-cohort metagenomic meta-analysis reveals robust, globally consistent metabolic and gene-level alterations in the gut microbiome of Parkinson’s disease patients, highlighting functional dysbiosis, oxidative stress responses, and disrupted microbial signaling as potential diagnostic and therapeutic targets.

Shotgun metagenomics of saliva and stool in early Parkinson’s disease reveals higher gut richness, disrupted microbial networks, and specific oral and gut microbiome signatures that classify PD, with saliva taxa and constipation-linked diversity closely tied to autonomic symptom burden.

This study generated a comprehensive set of gut metagenome-assembled genomes, revealing reduced Ruminococcus bromii diversity and loss of key metabolic genes in Parkinson’s disease, along with altered abundances of specific taxa and functional elements, providing valuable insights for microbiome signature databases and clinical research in PD.

This study used fecal 16S sequencing to identify microbial signatures distinguishing CKD from ESRD, highlighting depletion of SCFA-producing taxa and strong associations between microbiome structure and clinical markers, especially β₂-microglobulin.

What was reviewed? This review article examines how transition metals shape bacterial virulence through three interconnected processes: acquisition, limitation, and intoxication. It emphasizes the evolutionary “arms race” between microbial strategies for metal uptake and host mechanisms for nutritional immunity. The review highlights how iron, zinc, and manganese—critical cofactors for bacterial metabolism—are sequestered, restricted, or weaponized […]

This review explains how uremic toxins in ESRD drive cardiovascular, immune, and neurological injury, emphasizing toxin classification, toxicity indices, and the superiority of hemoadsorption and advanced membranes for removing hard-to-clear solutes.

This review explores how dietary fiber influences microbiome activity, uremic toxins, inflammation, and clinical outcomes in CKD, highlighting substantial benefits and the need for individualized, fiber-rich dietary approaches.

This review evaluates how clinical events during the transition from pre-ESRD to ESRD influence outcomes, highlighting fluid overload, abrupt eGFR decline, and cardiovascular stress as major determinants of early ESRD mortality.

This meta-analysis of shotgun gut microbiome datasets in Parkinson’s disease identified cross-country microbial and functional signatures, including reduced riboflavin and biotin biosynthesis, depleted SCFA and polyamine levels, and species-level taxonomic shifts—highlighting microbiome-driven metabolic deficits as potential contributors to PD pathogenesis.

This study compared causes of death in ESRD patients between USRDS and KPSC sources, finding low concordance and highlighting limitations in mortality attribution for clinical and translational research contexts.

The KDIGO 2012 CKD guideline synthesizes global evidence to refine CKD definition, staging, prognosis, and management, emphasizing albuminuria and GFR as core predictors of progression and mortality.

End-stage renal disease is the irreversible loss of kidney function marked by uremic toxin accumulation, systemic complications, and the need for dialysis or transplantation. Its pathophysiology involves nephron loss, inflammation, metabolic disruption, and microbiome-derived toxins that accelerate cardiovascular and immune dysfunction.

A synthesis of modular nephron replacement strategies, detailing organoids, iBKs, bioprinting, and scaffolds, with emphasis on vascularization challenges and hybrid system potential.

This review examines how the chronic kidney disease gut microbiome becomes dysbiotic, elevates uremic toxins, weakens the gut barrier, and accelerates renal and cardiovascular injury, highlighting therapeutic targets.